clearpoint neuro inc - CLPT
CLPT
Close Chg Chg %
9.10 0.04 0.44%
Closed Market
9.14
+0.04 (0.44%)
Volume: 446.61K
Last Updated:
Apr 1, 2026, 4:00 PM EDT
Company Overview: clearpoint neuro inc - CLPT
CLPT Key Data
| Open $9.16 | Day Range 9.05 - 9.48 |
| 52 Week Range 8.60 - 30.10 | Market Cap $269.94M |
| Shares Outstanding 29.66M | Public Float 25.65M |
| Beta 1.18 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.90 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.06M |
CLPT Performance
| 1 Week | 0.77% | ||
| 1 Month | -27.29% | ||
| 3 Months | -33.19% | ||
| 1 Year | -17.14% | ||
| 5 Years | -57.65% |
CLPT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
2
Full Ratings ➔
About clearpoint neuro inc - CLPT
ClearPoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.
CLPT At a Glance
ClearPoint Neuro, Inc.
120 South Sierra Avenue
Solana Beach, California 92075
| Phone | 1-888-287-9109 | Revenue | 36.97M | |
| Industry | Medical Specialties | Net Income | -25,540,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 17.78% | |
| Fiscal Year-end | 12 / 2026 | Employees | 172 | |
| View SEC Filings |
CLPT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 10.477 |
| Price to Book Ratio | 14.338 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -18.227 |
| Enterprise Value to Sales | 10.81 |
| Total Debt to Enterprise Value | 0.146 |
CLPT Efficiency
| Revenue/Employee | 214,947.674 |
| Income Per Employee | -148,488.372 |
| Receivables Turnover | 5.09 |
| Total Asset Turnover | 0.528 |
CLPT Liquidity
| Current Ratio | 5.894 |
| Quick Ratio | 5.118 |
| Cash Ratio | 4.266 |
CLPT Profitability
| Gross Margin | 61.191 |
| Operating Margin | -65.359 |
| Pretax Margin | -68.932 |
| Net Margin | -69.081 |
| Return on Assets | -36.465 |
| Return on Equity | -95.639 |
| Return on Total Capital | -29.611 |
| Return on Invested Capital | -44.824 |
CLPT Capital Structure
| Total Debt to Total Equity | 207.823 |
| Total Debt to Total Capital | 67.514 |
| Total Debt to Total Assets | 57.719 |
| Long-Term Debt to Equity | 205.346 |
| Long-Term Debt to Total Capital | 66.709 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Clearpoint Neuro Inc - CLPT
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 20.55M | 23.95M | 31.39M | 36.97M | |
Sales Growth
| +26.09% | +16.56% | +31.04% | +17.78% | |
Cost of Goods Sold (COGS) incl D&A
| 7.02M | 10.34M | 12.27M | 14.35M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 777.00K | 1.46M | 1.90M | 2.24M | |
Depreciation
| - | 1.03M | 1.12M | 2.07M | |
Amortization of Intangibles
| - | 426.00K | 780.00K | 168.00K | |
COGS Growth
| +40.18% | +47.31% | +18.63% | +16.95% | |
Gross Income
| 13.53M | 13.61M | 19.12M | 22.62M | |
Gross Income Growth
| +19.84% | +0.61% | +40.46% | +18.31% | |
Gross Profit Margin
| +65.84% | +56.83% | +60.92% | +61.19% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 29.86M | 36.06M | 38.87M | 46.79M | |
Research & Development
| 10.89M | 11.71M | 12.39M | 13.90M | |
Other SG&A
| 18.97M | 24.35M | 26.48M | 32.89M | |
SGA Growth
| +21.07% | +20.75% | +7.79% | +20.37% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (16.33M) | (22.45M) | (19.75M) | (24.16M) | |
Non Operating Income/Expense
| (22.00K) | 357.00K | 832.00K | 1.07M | |
Non-Operating Interest Income
| - | 386.00K | 872.00K | 1.21M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 81.00K | 2.39M | - |
Interest Expense Growth
| - | - | - | -91.68% | - |
Gross Interest Expense
| - | - | 81.00K | 2.39M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (16.43M) | (22.09M) | (18.91M) | (25.48M) | |
Pretax Income Growth
| -14.05% | -34.40% | +14.37% | -34.74% | |
Pretax Margin
| -79.97% | -92.21% | -60.25% | -68.93% | |
Income Tax
| - | - | - | 55.00K | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (16.43M) | (22.09M) | (18.91M) | (25.54M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (16.43M) | (22.09M) | (18.91M) | (25.54M) | |
Net Income Growth
| -14.05% | -34.40% | +14.37% | -35.03% | |
Net Margin Growth
| -79.97% | -92.21% | -60.25% | -69.08% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (16.43M) | (22.09M) | (18.91M) | (25.54M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (16.43M) | (22.09M) | (18.91M) | (25.54M) | |
EPS (Basic)
| -0.6796 | -0.8977 | -0.6998 | -0.902 | |
EPS (Basic) Growth
| +2.22% | -32.09% | +22.05% | -28.89% | |
Basic Shares Outstanding
| 24.18M | 24.61M | 27.03M | 28.32M | |
EPS (Diluted)
| -0.6796 | -0.8977 | -0.6998 | -0.902 | |
EPS (Diluted) Growth
| +2.22% | -32.09% | +22.05% | -28.89% | |
Diluted Shares Outstanding
| 24.18M | 24.61M | 27.03M | 28.32M | |
EBITDA
| (15.55M) | (20.99M) | (17.84M) | (21.93M) | |
EBITDA Growth
| -22.65% | -34.93% | +14.99% | -22.89% | |
EBITDA Margin
| -75.69% | -87.62% | -56.84% | -59.31% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 24.00 | |
| Number of Ratings | 2 | Current Quarters Estimate | -0.255 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -0.97 | |
| Last Quarter’s Earnings | -0.26 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.90 | Next Fiscal Year Estimate | -0.815 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 2 | 2 |
| Mean Estimate | -0.26 | -0.24 | -0.97 | -0.82 |
| High Estimates | -0.25 | -0.24 | -0.96 | -0.75 |
| Low Estimate | -0.26 | -0.24 | -0.98 | -0.88 |
| Coefficient of Variance | -2.77 | 0.00 | -1.46 | -11.28 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Clearpoint Neuro Inc - CLPT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Clearpoint Neuro Inc - CLPT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 17, 2026 | Joseph Michael Burnett CEO and President; Director | 139,061 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Jeremy L. Stigall Chief Business Officer | 123,633 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Jeremy L. Stigall Chief Business Officer | 108,482 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.53 per share | 1,250,797.46 |
| Mar 17, 2026 | Jeremy L. Stigall Chief Business Officer | 30,995 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Danilo D’Alessandro Chief Financial Officer | 32,626 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Danilo D’Alessandro Chief Financial Officer | 102,684 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.53 per share | 1,183,946.52 |
| Mar 17, 2026 | Danilo D’Alessandro Chief Financial Officer | 119,285 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Joseph Michael Burnett CEO and President; Director | 84,828 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Joseph Michael Burnett CEO and President; Director | 95,900 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.53 per share | 1,105,727.00 |
| Mar 17, 2026 | Mazin Sabra Chief Operating Officer | 67,343 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.53 per share | 776,464.79 |
| Mar 17, 2026 | Mazin Sabra Chief Operating Officer | 80,624 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Mazin Sabra Chief Operating Officer | 26,101 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Timothy T. Richards Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Pascal E. R. Girin Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Matthew B. Klein Director | 50,518 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Matthew B. Klein Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | R. John Fletcher Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | R. John Fletcher Director | 115,491 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Lynnette C. Fallon Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Lynnette C. Fallon Director | 51,101 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |